| http://www.w3.org/ns/prov#value | - As for launching Inflectra, Hospira licensed the drug (and seven other biosmilars) from South Korea???s Celltrion in 2009 for Europe and other markets, including the USA. Mr Greenland noted that for the territories in Europe where Remicade patents have expired, talks are ongoing regarding pricing and reimbursement and Hospira will launch its biosimilar once those discussions are completed.
|
